NCT00576433View on ClinicalTrials.gov

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Methotrexate

As prescribed

DRUG

rituximab [MabThera/Rituxan]

1000mg iv on days 1 and 15

Trial Locations (18)

115522

Moscow

150062

Yaroslavl

195067

Saint Petersburg

305007

Kursk

390026

Ryazan

394066

Voronezh

420012

Kazan'

450005

Ufa

454076

Chelyabinsk

603126

Nizhny Novgorod

620102

Yekaterinburg

625023

Tyumen

628011

Khanty-Mansiysk

630099

Novosibirsk

630117

Novosibirsk

664047

Irkutsk

680009

Khabarovsk

690050

Vladivostok

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00576433 - A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. | Biotech Hunter | Biotech Hunter